Chordate Medical's CEO Anders Weilandt discusses the subgroup analysis that has been presented from the company's PM007 study with K.O.S.-treatment for the prevention of chronic migraine. Weilandt is interviewed by Jens Jacob Aabel Nordkvist, analyst at Västra Hamnen Corporate Finance.